139 Results for "

LCK

" in MedChemExpress (MCE) Product Catalog:
Products (139)

139 Results for "LCK" in MCE Product Catalog:

  • Categories Recommended:
    More
4
4 Cited Publications
Cat. No.: HY-P99129

Research Areas:  

Inflammation/Immunology

Anti-Mouse CD8a Antibody (53-6.7) is an anti-mouse CD8a IgG2a antibody inhibitor derived from host Rat. Anti-Mouse CD8a Antibody (53-6.7) binds to CD8αβ stabilizes a conformation with a higher affinity for interaction with MHC class I. Anti-Mouse CD8a Antibody (53-6.7) induces the phosphorylation and activation of TCR proximal signaling pathway components Lck and ZAP70 in polyclonal memory T cells. Anti-Mouse CD8a Antibody (53-6.7) depletes CD8+ T cells and neutralizes cytokine in mice .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-10251
CAS No.: 714971-09-2
Synonyms: AC480
Target:  

EGFR

Research Areas:  

Cancer

BMS-599626 (AC480) is a selective and orally bioavailable HER1 and HER2 inhibitor, with IC50s of 20 and 30 nM, respectively. BMS-599626 displays ~8-fold less potent to HER4 (IC50=190 nM), >100-fold to VEGFR2, c-Kit, Lck, MEK. BMS-599626 inhibits tumor cell proliferation, and has potential to increase tumor response to radiotherapy .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-15590
CAS No.: 915720-21-7
Purity:  98.92%
Synonyms: AZD1332
Target:  

Trk Receptor

Research Areas:  

Cancer

AZ-23 is an ATP-competitive and orally bioavailable Trk kinase A/B/C inhibitor with IC50s of 2 nM (TrkA), 8 nM (TrkB), 24 nM (FGFR1), 52 nM (Flt3), 55 nM (Ret), 84 nM (MuSk), 99 nM (Lck), respectively.
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-10185
CAS No.: 867331-64-4
Purity:  98.96%
Target:  

Src VEGFR FGFR PDGFR

Research Areas:  

Inflammation/Immunology

TG 100572 Hydrochloride is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-18010
CAS No.: 330786-25-9
Target:  

Btk BCRP

Research Areas:  

Inflammation/Immunology

PCI 29732 is a potent, orally active, reversible BTK inhibitor with Ki app values of 8.2, 4.6, and 2.5 nM for BTK, Lck and Lyn, respectively. PCI 29732 shows only modest inhibitory activity against Itk, another Tec family kinase. PCI 29732 inhibits the function of ABCG2 by competitively binding to the ATP-binding site of ABCG2 .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-12010
CAS No.: 873837-23-1
Purity:  99.68%
Synonyms: AC480 Hydrochloride
Target:  

EGFR

Research Areas:  

Cancer

BMS-599626 Hydrochloride (AC480 Hydrochloride) is a selective and orally bioavailable HER1 and HER2 inhibitor, with IC50s of 20 and 30 nM, respectively. BMS-599626 Hydrochloride displays ~8-fold less potent to HER4 (IC50=190 nM), >100-fold to VEGFR2, c-Kit, Lck, MEK. BMS-599626 Hydrochloride inhibits tumor cell proliferation, and has potential to increase tumor response to radiotherapy .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-15196
CAS No.: 871026-44-7
Purity:  99.70%
Target:  

EGFR

Research Areas:  

Cancer

TAK-285 is a potent, selective, ATP-competitive and orally active HER2 and EGFR(HER1) inhibitor with IC50 of 17 nM and 23 nM, respectively. TAK-285 is >10-fold selectivity for HER1/2 than HER4, and less potent to MEK1/5, c-Met, Aurora B, Lck, CSK etc. TAK-285 has effective antitumor activity . TAK-285 can cross the blood-brain barrier (BBB) .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-18303
CAS No.: 882663-88-9
Target:  

Src VEGFR p38 MAPK JAK

Research Areas:  

Inflammation/Immunology

AMG-47a is an orally active, ATP-competitive Lck inhibitor (IC50=0.2 nM). AMG-47a inhibits VEGF2, p38α, p38α, Jak3, MLR, and IL-2 with IC50 of 1 nM, 3 nM, 72 nM, 30 nM, and 21 nM, respectively. AMG-47a reduces T cell activation and the production of cytokines such as TGF-β, exerting anti-inflammatory and anti-fibrotic activities. AMG-47a can be used in the research of autoimmune diseases, pulmonary fibrosis, and KRAS mutation-associated cancers[1][2][3].
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-12072
CAS No.: 847950-09-8
Purity:  99.92%
Target:  

Src

Research Areas:  

Inflammation/Immunology

Lck Inhibitor is a potent, orally active Lck (lymphocyte specific kinase) inhibitor with IC50s of 7, 2.1, 4.2 and 200 nM for Lck, Lyn, Src and Syk kinases, respectively. Lck Inhibitor shows >1000-fold selectivity for Lck over MAPK, CDK and RSK family representatives. Lck Inhibitor inhibits T cell proliferation and in vivo models of arthritis .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-108318
CAS No.: 213743-31-8
Purity:  99.91%
Synonyms: KIN 001-51
Target:  

Src

RK-24466 (KIN 001-51) is a potent and selective Lck inhibitor; inhibits Lck (64-509) and LckCD isoforms with IC50s of less than 1 and 2 nM, respectively.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-132166
CAS No.: 2590556-80-0
Purity:  99.47%
Synonyms: M4205; IDRX-42
Target:  

c-Kit PDGFR c-Fms FLT3 Src

Research Areas:  

Cancer

Velzatinib (M4205) is a multi-target inhibitor for PDGFRB, PDGFRA, CSF1R, c-Kit, FLT3, and LCK, with an IC50s of 2.6, 50, 5.5, 44, 141 and 141 nM, respectively. Velzatinib exhibits antitumor efficacy in xenograft mouse models .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P3279
CAS No.: 147612-86-0
Target:  

Src

Research Areas:  

Cancer

EPQpYEEIPIYL, a phosphopeptide, is a Src homology 2 (SH2) domain ligand. EPQpYEEIPIYL activates Src family members (e.g. Lck, Hck, Fyn) by binding to SH2 domains .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-18302
CAS No.: 1003311-62-3
Target:  

c-Kit

Research Areas:  

Inflammation/Immunology

c-Kit-IN-5 is potent inhibitor of c-Kit, with IC50s of 22 nM and 16 nM in kinase assay and cell assay, respectively. c-Kit-IN-5 shows more than 200-fold selectivity for c-Kit over KDR, p38, Lck, and Src. c-Kit-IN-5 also exhibits desirable pharmacokinetic properties .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P73269
Purity:  ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: LCK; P56(LSTRA) Protein-Tyrosine Kinase; LCK Proto-Oncogene, Src Family Tyrosine Kinase; Tyrosine-Protein Kinase; Lymphocyte Cell-Specific Protein-Tyrosine Kinase; Proto-Oncogene LCK; T Cell-Specific Protein-Tyrosine Kinase; Protein YT16; Leukocyte C-Term
Species:  
Human
Source:  
Sf9 insect cells
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-10186
CAS No.: 867331-82-6
Purity:  98.61%
Target:  

VEGFR FGFR PDGFR Src

Research Areas:  

Cancer

TG 100801 is a proagent that generates TG 100572 by de-esterification in development to treat age-related macular degeneration. TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P80518
Synonyms: ORCA, OSIL, SQSTM1, Sequestosome-1, EBI3-associated protein of 60 kDa, Phosphotyrosine-independent ligand for the LCK SH2 domain of 62 kDa, Ubiquitin-binding protein p62, EBIAP, p60, p62

Host:  

Mouse

Application:  

IHC-P, FC

Reactivity:  

Human, Mouse, Rat

loading...
    loading...
Cat. No.: HY-W062835
CAS No.: 234772-64-6
Target:  

Src

Research Areas:  

Cancer

CGP77675 is an orally active and potent inhibitor of Src family kinases. CGP77675 inhibits phosphorylation of peptide substrates and autophosphorylation of purified Src (IC50s of 5-20 and 40 nM, respectively), and also inhibits Src, EGFR, KDR, v-Abl, and Lck with IC50s of 5-20, 40, 20, 150, 1000, 310, and 290 nM, respectively. Anticancer activity .
loading...
    loading...
Cat. No.: HY-10644
CAS No.: 944795-06-6
Purity:  99.73%
Target:  

Src Btk Syk

Research Areas:  

Others

Lck inhibitor 2 is a bisanilino pyrimidine-derived tyrosine kinase inhibitor targeting LCK, BTK, LYN, SYK and TXK, with a Kd value of 10 nM against TXK .
loading...
    loading...
Cat. No.: HY-108485
CAS No.: 477-84-9
Purity:  ≥98.0%
Damnacanthal is an anthraquinone isolated from the root of Morinda citrifolia. Damnacanthal is a highly potent, selective inhibitor of p56 lck tyrosine kinase activity. Natural Damnacanthal inhibits p56 lck autophosphorylation and phosphorylation of exogenous substrates with IC50s of 46 nM and 220 nM, respectively. Damnacanthal is a potent inducer of apoptosis with anticancer activity. Damnacanthal also has antinociceptive, anti-inflammatory effects in mice and anti-fungal activity against Candida albicans .
loading...
    loading...
Cat. No.: HY-12847
CAS No.: 1163719-91-2
Target:  

Raf Src Apoptosis

Research Areas:  

Cancer

CCT241161 is an orally active pan-RAF inhibitor with IC50s of 3, 6, 10, 15 and 30 nM for LCK, CRAF, SRC, V600E-BRAF and BRAF, respectively. CCT241161 shows good activity to in BRAF and NRAS mutant melanomas. CCT241161 also exhibits anticancer cell proliferative activity .
loading...
    loading...